Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17734770 | 1.00 | MAPT (0.33) | MAPTTYMSTNKS2PDE10ATAAR1 | |
| SCHEMBL17734772 | 0.95 | TYMS (0.36) | MAPTTYMSTNKS2 | |
| SCHEMBL3369978 | 0.91 | TNKS2 (0.37) | MAPTTYMSTNKS2PDE10ATAAR1 | |
| SCHEMBL17734750 | 0.90 | CYP3A4 (0.33) | MAPTALDH1A1KDM4E | |
| SCHEMBL17368989 | 0.89 | ALDH1A1 (0.38) | MAPTTAAR1ALDH1A1HPGDKDM4E | |
| SCHEMBL19393440 | 0.89 | ALDH1A1 (0.38) | MAPTTAAR1ALDH1A1HPGDKDM4E | |
| SCHEMBL14179895 | 0.88 | ALDH1A1 (0.39) | MAPTTNKS2PDE10ATAAR1HPRT1 | |
| SCHEMBL2887338 | 0.88 | ALDH1A1 (0.39) | MAPTTAAR1ALDH1A1HPGDKDM4E | |
| SCHEMBL17734766 | 0.87 | MAPT (0.37) | MAPTTYMSNPC1RAB9AHPRT1 | |
| SCHEMBL17734768 | 0.87 | MAPT (0.37) | MAPTTYMSNPC1RAB9AHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160133847-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160133847-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160133847-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT | ARL1, CCNL2, APOL1 | MAPT 3931/4885TYMS 4657/4885TNKS2 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.